Mifegyne

Mifepristone, the active ingredient in Mifegyne, is a progesterone receptor antagonist presented as a tablet for oral use. It is employed for the medical termination of intrauterine pregnancy and for managing early pregnancy loss in women of reproductive age under strict medical supervision and in accordance with national guidelines.

GNH USA supplies Mifegyne as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures reliable access to quality‑assured products across multiple regions while complying with all applicable regulatory requirements.

Mifegyne (mifepristone) is used in reproductive health for conditions that require progesterone antagonism.

Medical termination of intrauterine pregnancy: induces uterine lining breakdown and detachment of the embryo to achieve a non‑surgical abortion. Cervical ripening prior to surgical abortion: softens the cervix to facilitate subsequent procedural abortion. Management of early pregnancy loss: assists in the expulsion of retained products after a miscarriage.

Adverse reactions may occur with Mifegyne use.

Common Side Effects: - Nausea: mild to moderate feeling of sickness. - Vomiting: occasional episodes. - Abdominal pain or cramping: uterine discomfort. - Vaginal bleeding: spotting or heavier flow. - Diarrhea: loose stools. - Fatigue: generalized tiredness.

Serious or Rare Side Effects: - Severe hemorrhage: heavy bleeding requiring medical attention. - Infection: signs of uterine or systemic infection. - Allergic reaction: rash, itching, swelling, or anaphylaxis. - Incomplete abortion: retained tissue requiring surgical intervention.

Mifegyne should be used with careful clinical oversight. - Medical supervision: use only under qualified health‑care provider guidance. - Gestational age limit: prescribed up to 10 weeks gestation for termination. - Contraindications: not for women with chronic adrenal failure, long‑term corticosteroid therapy, or known hypersensitivity. - Drug interactions: review concomitant medications, especially anticoagulants and CYP inducers. - Follow‑up care: ensure appropriate post‑treatment evaluation for completeness. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in original packaging.

Mifegyne may interact with several medicines; monitoring is essential.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased risk of severe bleeding. - Systemic corticosteroids: reduced efficacy due to glucocorticoid antagonism. - Rifampicin and other CYP3A4 inducers: lower plasma levels of mifepristone. - Antifungal azoles (e.g., ketoconazole): may increase mifepristone exposure, raising toxicity risk.

Moderate Interactions (Monitor Closely): - NSAIDs: may affect uterine bleeding patterns. - Antihypertensives: monitor blood pressure changes. - Antidepressants (SSRIs): observe for altered hormonal effects.